https://novapharmanews.com/eu/news/eye-drugs-list-sodium-hyaluronate-tafluprost-tobramycin-uses 2026-06-08T03:10:08.723Z NovaPharmaNews en 2026-06-08T01:03:26.318Z Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses Sodium cromoglicate, Sodium hyaluronate, Soybean oil, Tafluprost, Timolol, Tobramycin, Travoprost, Tropicamide, bimatoprost, Lumigan https://novapharmanews.com/uploads/articles/eye-drugs-list-sodium-hyaluronate-tafluprost-tobramycin-uses.webp Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses https://novapharmanews.com/apac/news/areas-with-risk-of-dengue-cdc-map-criteria-global-reach 2026-06-08T01:47:48.925Z NovaPharmaNews en 2026-06-08T00:03:48.011Z Areas with Risk of Dengue: CDC map, criteria, and global reach Dengue Vaccine, Dengue https://novapharmanews.com/uploads/articles/areas-with-risk-of-dengue-cdc-map-criteria-global-reach.webp Areas with Risk of Dengue: CDC map, criteria, and global reach https://novapharmanews.com/us/news/breast-cancer-statistics-worldwide-what-the-data-shows 2026-06-08T06:40:16.752Z NovaPharmaNews en 2026-06-07T22:35:48.748Z Breast Cancer Statistics Worldwide: What the Data Shows breast cancer, invasive breast cancer https://novapharmanews.com/uploads/articles/breast-cancer-statistics-worldwide-what-the-data-shows.webp Breast Cancer Statistics Worldwide: What the Data Shows https://novapharmanews.com/us/news/manufacturing-pipeline-approvals-evidence-confirms 2026-06-08T06:40:12.747Z NovaPharmaNews en 2026-06-07T22:35:31.561Z Manufacturing pipeline approvals: what the evidence confirms https://novapharmanews.com/uploads/articles/manufacturing-pipeline-approvals-evidence-confirms.webp Manufacturing pipeline approvals: what the evidence confirms https://novapharmanews.com/us/news/glp-1-usage-statistics-data-shows 2026-06-08T06:40:10.923Z NovaPharmaNews en 2026-06-07T22:20:32.059Z GLP-1 usage statistics show broad uptake and mixed clinical signals GIP, GLP-1, weight loss, type 2 diabetes, heart disease, dementia, addiction, kidney problems, pancreas problems, gastrointestinal problems https://novapharmanews.com/uploads/articles/glp-1-usage-statistics-data-shows.webp GLP-1 usage statistics show broad uptake and mixed clinical signals https://novapharmanews.com/us/news/novo-nordisk-supply-wegovy-stabilizes-new-manufacturing-capacity 2026-06-08T06:39:48.966Z NovaPharmaNews en 2026-06-07T21:42:54.210Z Novo Nordisk supply of Wegovy stabilizes as new capacity comes online Wegovy, Ozempic, weight loss https://novapharmanews.com/uploads/articles/novo-nordisk-supply-wegovy-stabilizes-new-manufacturing-capacity.webp Novo Nordisk supply of Wegovy stabilizes as new capacity comes online https://novapharmanews.com/us/news/biontech-first-patient-phase-1-pancreatic-cancer-mrna-vaccine-trial 2026-06-08T06:40:04.657Z NovaPharmaNews en 2026-06-07T21:31:51.033Z BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial autogene cevumeran, pancreatic cancer https://novapharmanews.com/uploads/articles/biontech-first-patient-phase-1-pancreatic-cancer-mrna-vaccine-trial.webp BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial https://novapharmanews.com/us/news/maritide-phase-2-obesity-data-20-percent-weight-loss-one-year 2026-06-08T03:22:06.597Z NovaPharmaNews en 2026-06-07T21:29:56.813Z MariTide Phase 2 obesity data show up to 20% weight loss at one year MariTide, maridebart cafraglutide, obesity, Type 2 diabetes https://novapharmanews.com/uploads/articles/maritide-phase-2-obesity-data-20-percent-weight-loss-one-year.webp MariTide Phase 2 obesity data show up to 20% weight loss at one year https://novapharmanews.com/us/news/gsk-blenrep-returns-us-market-fda-approves-resubmission 2026-06-08T06:39:54.756Z NovaPharmaNews en 2026-06-07T21:27:36.680Z GSK’s Blenrep returns to the US market after FDA approves resubmission Blenrep, belantamab mafodotin-blmf, bortezomib, dexamethasone, blood cancer, multiple myeloma, relapsed or refractory multiple myeloma https://novapharmanews.com/uploads/articles/gsk-blenrep-returns-us-market-fda-approves-resubmission.webp GSK’s Blenrep returns to the US market after FDA approves resubmission https://novapharmanews.com/us/news/moderna-mrna-1083-phase-3-flu-covid-immune-response 2026-06-08T06:40:18.820Z NovaPharmaNews en 2026-06-07T21:25:47.848Z Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response mRNA-1083, COVID-19, flu, influenza https://novapharmanews.com/uploads/articles/moderna-mrna-1083-phase-3-flu-covid-immune-response.webp Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response https://novapharmanews.com/us/news/danuglipron-phase-3-pfizer-phase-2b-obesity-trial 2026-06-08T03:19:58.930Z NovaPharmaNews en 2026-06-07T21:16:41.167Z Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win danuglipron, PF-06882961, orforglipron, obesity, GLP-1 https://novapharmanews.com/uploads/articles/danuglipron-phase-3-pfizer-phase-2b-obesity-trial.webp Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win https://novapharmanews.com/us/news/biogen-eisai-expand-leqembi-access-subcutaneous-maintenance-dosing 2026-06-08T03:00:32.927Z NovaPharmaNews en 2026-06-07T21:10:10.321Z Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing Leqembi, lecanemab-irmb, Alzheimer's disease https://novapharmanews.com/uploads/articles/biogen-eisai-expand-leqembi-access-subcutaneous-maintenance-dosing.webp Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing https://novapharmanews.com/us/news/fda-approves-vyloy-her2-negative-gastric-gej-cancer 2026-06-08T02:45:23.380Z NovaPharmaNews en 2026-06-07T20:33:14.356Z FDA approves Vyloy for HER2-negative gastric and GEJ cancer Vyloy, zolbetuximab, zolbetuximab-clzb, HER2-negative gastric cancer, gastric cancer, gastroesophageal junction adenocarcinoma https://novapharmanews.com/uploads/articles/fda-approves-vyloy-her2-negative-gastric-gej-cancer.webp FDA approves Vyloy for HER2-negative gastric and GEJ cancer https://novapharmanews.com/us/news/novo-nordisk-supply-of-wegovy-stabilizes-as-fda-shortage-ends 2026-06-08T03:53:44.681Z NovaPharmaNews en 2026-06-07T20:30:39.224Z Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends Wegovy, Ozempic, weight-loss https://novapharmanews.com/uploads/articles/novo-nordisk-supply-of-wegovy-stabilizes-as-fda-shortage-ends.webp Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends https://novapharmanews.com/us/news/jj-reports-positive-phase-3-tremfya-data-ulcerative-colitis 2026-06-08T01:33:03.208Z NovaPharmaNews en 2026-06-07T20:24:39.862Z J&J reports positive Phase 3 Tremfya data in ulcerative colitis Tremfya, guselkumab, ulcerative colitis, Inflammatory Bowel Disease https://novapharmanews.com/uploads/articles/jj-reports-positive-phase-3-tremfya-data-ulcerative-colitis.webp J&J reports positive Phase 3 Tremfya data in ulcerative colitis https://novapharmanews.com/us/news/sanofi-completes-inhibrx-acquisition-for-1-7b 2026-06-08T04:43:49.893Z NovaPharmaNews en 2026-06-07T20:19:42.007Z Sanofi completes Inhibrx acquisition for $1.7B inflammation https://novapharmanews.com/uploads/articles/sanofi-completes-inhibrx-acquisition-for-1-7b.webp Sanofi completes Inhibrx acquisition for $1.7B https://novapharmanews.com/us/news/mari-tide-phase-2-amgen-reports-up-to-20-percent-weight-loss-at-one-year 2026-06-08T03:27:10.647Z NovaPharmaNews en 2026-06-07T20:17:11.641Z MariTide Phase 2: Amgen reports up to 20% weight loss at one year MariTide, maridebart cafraglutide, obesity, Type 2 diabetes https://novapharmanews.com/uploads/articles/mari tide-phase-2-amgen-reports-up-to-20-percent-weight-loss-at-one-year.webp MariTide Phase 2: Amgen reports up to 20% weight loss at one year https://novapharmanews.com/us/news/fda-approves-dupixent-for-copd-eosinophilic-phenotype 2026-06-08T03:21:41.845Z NovaPharmaNews en 2026-06-07T20:15:04.437Z FDA approves Dupixent for COPD with eosinophilic phenotype Dupixent, dupilumab, chronic obstructive pulmonary disease, COPD, eosinophilic phenotype, type 2 inflammation https://novapharmanews.com/uploads/articles/fda-approves-dupixent-for-copd-eosinophilic-phenotype.webp FDA approves Dupixent for COPD with eosinophilic phenotype https://novapharmanews.com/us/news/gsk-blenrep-fda-approval-relapsed-multiple-myeloma 2026-06-08T03:07:27.000Z NovaPharmaNews en 2026-06-07T20:13:34.293Z GSK Blenrep wins FDA approval in relapsed multiple myeloma Blenrep, belantamab mafodotin-blmf, bortezomib, dexamethasone, blood cancer, multiple myeloma, relapsed or refractory multiple myeloma https://novapharmanews.com/uploads/articles/gsk-blenrep-fda-approval-relapsed-multiple-myeloma.webp GSK Blenrep wins FDA approval in relapsed multiple myeloma https://novapharmanews.com/us/news/modernas-mrna-1083-phase-3-stronger-flu-covid-immune-responses 2026-06-08T03:51:34.197Z NovaPharmaNews en 2026-06-07T20:10:30.299Z Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses mRNA-1083, COVID-19, influenza, flu https://novapharmanews.com/uploads/articles/modernas-mrna-1083-phase-3-stronger-flu-covid-immune-responses.webp Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses https://novapharmanews.com/us/news/merck-harpoon-therapeutics-acquisition-oncology-pipeline 2026-06-08T03:53:28.074Z NovaPharmaNews en 2026-06-07T20:03:21.825Z Merck’s Harpoon acquisition deepens oncology pipeline ahead of Keytruda risk Keytruda, oncology, cancer https://novapharmanews.com/uploads/articles/merck-harpoon-therapeutics-acquisition-oncology-pipeline.webp Merck’s Harpoon acquisition deepens oncology pipeline ahead of Keytruda risk https://novapharmanews.com/us/news/pfizer-danuglipron-phase-2b-obesity-endpoint 2026-06-08T03:13:15.801Z NovaPharmaNews en 2026-06-07T19:59:06.555Z Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint danuglipron, PF-06882961, orforglipron, obesity, GLP-1 https://novapharmanews.com/uploads/articles/pfizer-danuglipron-phase-2b-obesity-endpoint.webp Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint https://novapharmanews.com/us/news/roche-positive-phase-3-trontinemab-alzheimers-disease 2026-06-08T05:04:09.236Z NovaPharmaNews en 2026-06-07T19:55:13.717Z Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease trontinemab, Alzheimer's disease https://novapharmanews.com/uploads/articles/roche-positive-phase-3-trontinemab-alzheimers-disease.webp Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease https://novapharmanews.com/us/news/fda-approves-keytruda-adjuvant-nsclc-merck 2026-06-08T06:55:04.409Z NovaPharmaNews en 2026-06-07T19:06:26.690Z FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label pembrolizumab, Keytruda, lung cancer, non-small cell lung cancer https://novapharmanews.com/uploads/articles/fda-approves-keytruda-adjuvant-nsclc-merck.webp FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label https://novapharmanews.com/us/news/fda-approves-mercks-keytruda-adjuvant-nsclc-treatment 2026-06-08T03:53:19.499Z NovaPharmaNews en 2026-06-07T18:19:15.311Z FDA approves Merck’s Keytruda for adjuvant NSCLC treatment pembrolizumab, Keytruda, lung cancer, non-small cell lung cancer https://novapharmanews.com/uploads/articles/fda-approves-mercks-keytruda-adjuvant-nsclc-treatment.webp FDA approves Merck’s Keytruda for adjuvant NSCLC treatment https://novapharmanews.com/us/news/eli-lilly-donanemab-wins-fda-approval-early-alzheimers-disease 2026-06-08T02:53:40.872Z NovaPharmaNews en 2026-06-07T17:41:03.957Z Eli Lilly's donanemab wins FDA approval for early Alzheimer's disease donanemab, donanemab-azbt, Kisunla, Alzheimer's disease, mild cognitive impairment, mild dementia https://novapharmanews.com/uploads/articles/eli-lilly-donanemab-wins-fda-approval-early-alzheimers-disease.webp Eli Lilly's donanemab wins FDA approval for early Alzheimer's disease https://novapharmanews.com/us/news/fda-approves-keytruda-adjuvant-nsclc-merck-catalyst 2026-06-08T07:27:33.092Z NovaPharmaNews en 2026-06-07T17:37:19.377Z FDA approves Keytruda for adjuvant NSCLC, a Merck catalyst pembrolizumab, Keytruda, lung cancer, non-small cell lung cancer https://novapharmanews.com/uploads/articles/fda-approves-keytruda-adjuvant-nsclc-merck-catalyst.webp FDA approves Keytruda for adjuvant NSCLC, a Merck catalyst https://novapharmanews.com/us/news/fda-approves-keytruda-adjuvant-nsclc-early-stage-lung-cancer 2026-06-08T08:07:36.604Z NovaPharmaNews en 2026-06-07T16:59:48.001Z FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer pembrolizumab, Keytruda, oncology, NSCLC, lung cancer, non-small cell lung cancer https://novapharmanews.com/uploads/articles/fda-approves-keytruda-adjuvant-nsclc-early-stage-lung-cancer.webp FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer https://novapharmanews.com/us/news/fda-approves-keytruda-adjuvant-nsclc-merck-investor-watch 2026-06-08T06:39:59.117Z NovaPharmaNews en 2026-06-07T15:41:22.843Z FDA approves Keytruda adjuvant NSCLC use: what Merck investors should watch pembrolizumab, Keytruda, oncology, NSCLC, lung cancer, non-small cell lung cancer https://novapharmanews.com/uploads/articles/fda-approves-keytruda-adjuvant-nsclc-merck-investor-watch.webp FDA approves Keytruda adjuvant NSCLC use: what Merck investors should watch https://novapharmanews.com/us/news/novo-nordisk-cagrisema-phase-3-obesity-results-catalyst 2026-06-08T01:33:09.717Z NovaPharmaNews en 2026-06-07T14:28:00.726Z Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst CagriSema, Keytruda, pembrolizumab, tirzepatide, Zepbound, oncology, NSCLC, obesity, non-small cell lung cancer, type 2 diabetes https://novapharmanews.com/uploads/articles/novo-nordisk-cagrisema-phase-3-obesity-results-catalyst.webp Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst https://novapharmanews.com/apac/news/fosun-pharma-aribio-option-agreement 2026-06-08T01:33:15.732Z NovaPharmaNews en 2026-06-07T08:14:37.642Z Fosun Pharma and AriBio Forge Alzheimer's Option Agreement: Deal Intelligence Alzheimer's https://novapharmanews.com/uploads/articles/fosun-pharma-aribio-option-agreement.webp Fosun Pharma and AriBio Forge Alzheimer's Option Agreement: Deal Intelligence https://novapharmanews.com/us/news/triple-hormone-receptor-agonist-retatrutide-obesity-phase-3-results 2026-06-08T08:03:39.587Z NovaPharmaNews en 2026-06-07T08:14:07.662Z Triple Hormone-Receptor Agonist Retatrutide for Obesity: Phase 3 Results and Market Impact obesity https://novapharmanews.com/uploads/articles/triple-hormone-receptor-agonist-retatrutide-obesity-phase-3-results.webp Triple Hormone-Receptor Agonist Retatrutide for Obesity: Phase 3 Results and Market Impact https://novapharmanews.com/us/news/fda-industry-friendly-gene-therapy-guidance-bd 2026-06-08T02:01:49.097Z NovaPharmaNews en 2026-06-07T08:13:53.573Z Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know gene therapy https://novapharmanews.com/uploads/articles/fda-industry-friendly-gene-therapy-guidance-bd.webp Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know https://novapharmanews.com/us/news/johnson-and-johnson-asco-2026-data-adds-depth-to-jnj-valuation-story 2026-06-08T01:33:07.719Z NovaPharmaNews en 2026-06-07T08:13:35.807Z Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story oncology, autoimmunity, myeloma https://novapharmanews.com/uploads/articles/johnson-and-johnson-asco-2026-data-adds-depth-to-jnj-valuation-story.webp Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story https://novapharmanews.com/us/news/pfizer-berobenatide-obesity-drug-vesper-3-data 2026-06-08T01:33:24.248Z NovaPharmaNews en 2026-06-07T08:13:10.848Z Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook berobenatide, obesity https://novapharmanews.com/uploads/articles/pfizer-berobenatide-obesity-drug-vesper-3-data.webp Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook https://novapharmanews.com/us/news/puma-biotechnology-inducement-awards-nasdaq-5635c4-june-2026 2026-06-08T08:18:03.729Z NovaPharmaNews en 2026-06-07T08:12:47.704Z Puma Biotechnology Inducement Awards: Strategic Talent Moves Under Nasdaq Rule 5635(c)(4) https://novapharmanews.com/uploads/articles/puma-biotechnology-inducement-awards-nasdaq-5635c4-june-2026.webp Puma Biotechnology Inducement Awards: Strategic Talent Moves Under Nasdaq Rule 5635(c)(4) https://novapharmanews.com/eu/news/world-lightproof-bottle-opaque-liners-market-pharma-growth-2035 2026-06-08T06:39:34.790Z NovaPharmaNews en 2026-06-07T08:12:35.529Z World Lightproof Bottle Opaque Liners Market: Pharma Growth to 2035 https://novapharmanews.com/uploads/articles/world-lightproof-bottle-opaque-liners-market-pharma-growth-2035.webp World Lightproof Bottle Opaque Liners Market: Pharma Growth to 2035 https://novapharmanews.com/apac/news/pmda-regulatory-updates-orphan-drug-portal-asean-symposium 2026-06-08T01:33:23.737Z NovaPharmaNews en 2026-06-07T02:25:12.639Z PMDA Regulatory Updates: New Orphan Drug Portal and ASEAN Symposium Open https://novapharmanews.com/uploads/articles/pmda-regulatory-updates-orphan-drug-portal-asean-symposium.webp PMDA Regulatory Updates: New Orphan Drug Portal and ASEAN Symposium Open https://novapharmanews.com/eu/news/emea-2026-life-sciences-industry-cluster-report-market-analysis 2026-06-08T03:00:43.231Z NovaPharmaNews en 2026-06-07T02:19:50.643Z EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors https://novapharmanews.com/uploads/articles/emea-2026-life-sciences-industry-cluster-report-market-analysis.webp EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors https://novapharmanews.com/us/news/facet-life-sciences-appoints-frank-closurdo-vp-commercial-services 2026-06-08T06:25:52.721Z NovaPharmaNews en 2026-06-07T02:12:01.161Z Facet Life Sciences Appoints Frank Closurdo as VP, Commercial Services https://novapharmanews.com/uploads/articles/facet-life-sciences-appoints-frank-closurdo-vp-commercial-services.webp Facet Life Sciences Appoints Frank Closurdo as VP, Commercial Services https://novapharmanews.com/us/news/pfizer-berobenatide-monthly-obesity-drug-phase-2b-data 2026-06-08T01:34:24.787Z NovaPharmaNews en 2026-06-06T16:43:02.041Z Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b berobenatide, obesity https://novapharmanews.com/uploads/articles/pfizer-berobenatide-monthly-obesity-drug-phase-2b-data.webp Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b https://novapharmanews.com/us/news/listeria-outbreak-soft-cheese-fda-investigation 2026-06-08T01:33:48.757Z NovaPharmaNews en 2026-06-06T16:39:40.143Z Listeria Outbreak in Soft Cheese: FDA Investigation and Industry Impact Listeria monocytogenes infections https://novapharmanews.com/uploads/articles/listeria-outbreak-soft-cheese-fda-investigation.webp Listeria Outbreak in Soft Cheese: FDA Investigation and Industry Impact https://novapharmanews.com/us/news/cdc-ebola-outbreak-central-africa-20000-cases-2026 2026-06-08T05:07:04.024Z NovaPharmaNews en 2026-06-06T10:31:46.119Z CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures Ebola https://novapharmanews.com/uploads/articles/cdc-ebola-outbreak-central-africa-20000-cases-2026.webp CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures